MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Multi-Pathogen Vaccine Kit
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Multi-Pathogen Vaccine Kit
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • Uncategorized
  • AIVITA Biomedical Announces U.S. Food and Drug Administration Clearance of IND for Phase II Glioblastoma Multiforme Trial

Recent Posts

  • AIVITA Biomedical Licenses Novel Skincare Formulations to Global Skincare Retailer LevEllis
  • AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress
  • AIVITA Biomedical Strengthens Board of Directors with Appointment of Ex-Biogen CEO Michel Vounatsos
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Present at Biotech Showcase 2024

Recent Comments

    Archives

    • October 2024
    • April 2024
    • February 2024
    • January 2024
    • October 2023
    • September 2023
    • July 2023
    • June 2023
    • April 2023
    • March 2023
    • January 2023
    • November 2022
    • October 2022
    • September 2022
    • August 2022
    • April 2022
    • March 2022
    • November 2021
    • October 2021
    • September 2021
    • July 2021
    • June 2021
    • December 2020
    • November 2020
    • August 2020
    • July 2020
    • April 2020
    • February 2020
    • January 2020
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • December 2017
    • November 2017
    • September 2017
    • June 2017
    • May 2017
    • April 2017
    • February 2017
    • September 2016
    • July 2016
    • June 2016

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    AIVITA Biomedical is a biotechnology company developing personalized vaccines that target infectious diseases and tumor-initiating cells — the seed of all cancers — using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

    Recent News

    • AIVITA Biomedical Licenses Novel Skincare Formulations to Global Skincare Retailer LevEllis
    • AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
    • AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress
    • AIVITA Biomedical Strengthens Board of Directors with Appointment of Ex-Biogen CEO Michel Vounatsos
    • AIVITA Biomedical CEO Dr. Hans Keirstead to Present at Biotech Showcase 2024

    Site Navigation

    • About Us
    • Programs
    • News & Media
    • Contact Us
    Copyright © 2023 | AIVITA Biomedical, Inc.